Cannabis and Chronic Pain
What the evidence actually says about cannabis for long-term pain, separated from the marketing and the moral panic.
Cannabis is not a miracle pain killer, and it's not snake oil either. The best evidence shows modest benefit for neuropathic pain and some cancer pain — roughly on par with, or slightly weaker than, existing options. For most other chronic pain conditions, the data is thin or mixed. Many people get real relief; many people don't. The honest answer is 'it works for some people, for some pain types, with real trade-offs,' and anyone selling certainty in either direction is selling something.
Not Medical Advice
This article is educational, not medical advice. Chronic pain has many causes, and cannabis interacts with medications (especially opioids, benzodiazepines, blood thinners, and some antidepressants). Talk to a clinician who actually knows your case before starting, stopping, or substituting any treatment. If you are pregnant, have a personal or family history of psychosis, or have serious cardiovascular disease, the risk profile changes significantly.
Plain-Language Summary
Across dozens of randomized trials and several large systematic reviews, cannabis and cannabis-based medicines produce a small-to-moderate reduction in chronic pain for some people. The most-cited number, from the 2017 National Academies report, is that there is 'substantial evidence' that cannabis is effective for chronic pain in adults [1] Strong evidence. Later reviews have tempered that conclusion: the effect is real but modest, and the quality of evidence varies a lot by pain type [2][3] Strong evidence.
A useful rule of thumb from the trials: about 1 in 3 patients gets a clinically meaningful (≥30%) reduction in pain, versus about 1 in 5 on placebo [2] Strong evidence. That's a real signal, but it's not the dramatic relief that dispensary marketing implies.
What Probably Works
Neuropathic pain. This is the strongest indication. Multiple RCTs of inhaled cannabis, oral THC, and the THC/CBD spray nabiximols (Sativex) show modest reductions in nerve-related pain — diabetic neuropathy, HIV-associated neuropathy, post-surgical nerve pain, multiple sclerosis-related pain [2][4] Strong evidence. Nabiximols is approved in the UK, Canada, Germany, and elsewhere specifically for MS-related neuropathic pain and spasticity [5] Strong evidence.
Cancer pain (as add-on). Evidence is weaker but consistent: cannabinoids added to opioids may reduce pain or allow lower opioid doses in some cancer patients [3] Weak / limited. Not a first-line treatment, but a reasonable adjunct.
MS-related spasticity-associated pain. Nabiximols has the clearest regulatory evidence here [5] Strong evidence.
What Might Work
Fibromyalgia. Small trials of nabilone and inhaled cannabis show some benefit on pain and sleep, but studies are small and short [6] Weak / limited.
Chronic headache and migraine. Survey and observational data suggest many users report relief, but controlled trials are sparse [7] Weak / limited. The folklore here far outpaces the data.
Opioid-sparing. Observational studies in legal-cannabis states show some patients reduce opioid doses [8] Disputed. The early ecological studies suggesting cannabis laws reduced opioid overdose deaths have not held up in longer-term analyses [9] Disputed. Individual opioid-sparing is plausible; population-level effects are unclear.
CBD alone for pain. Despite massive marketing, high-quality RCTs of isolated CBD for chronic pain are limited and mostly negative or inconclusive [10] Weak / limited. Most positive cannabinoid trials use THC or THC+CBD, not CBD alone.
What Doesn't Work (Or Is Probably Marketing)
- 'Indica for pain, sativa for energy.' The indica/sativa split does not reliably predict chemical content or clinical effects [11] Strong evidence. It's folklore.
- Specific terpene thresholds (e.g., 'myrcene above 0.5% makes it sedating'). There is no good clinical evidence for this claim No data.
- CBD topicals for deep joint or nerve pain. Skin absorption of CBD is poor and clinical evidence is thin Weak / limited. They may help superficial musculoskeletal soreness, but they're not treating arthritis at the joint.
- Curing the underlying cause. Cannabis modulates pain perception. It is not disease-modifying for arthritis, neuropathy, or cancer.
What We Don't Know
- Optimal dose and ratio. Trials use wildly different products and doses. There is no settled THC:CBD ratio for any pain condition No data.
- Long-term efficacy. Most RCTs run weeks to a few months. Whether tolerance develops to the analgesic effect over years is unclear [3] Weak / limited.
- Whole-plant vs. isolated cannabinoids. The 'entourage effect' is a plausible hypothesis with weak direct clinical evidence Weak / limited.
- Who responds. No reliable biomarker or patient characteristic predicts who the ~30% of responders are.
- Minor cannabinoids (CBG, CBN, THCV). Marketed aggressively for pain; almost no controlled human data No data.
Comparison With Standard Treatments
Effect sizes for cannabinoids in chronic pain trials are roughly comparable to — or somewhat smaller than — gabapentinoids (gabapentin, pregabalin) and tricyclic antidepressants for neuropathic pain [2][4] Strong evidence. They are generally weaker than opioids for acute and cancer pain but with a very different risk profile: cannabis carries essentially zero acute overdose risk, while opioids cause tens of thousands of overdose deaths per year in the US [12] Strong evidence.
For non-neuropathic chronic pain (low back pain, osteoarthritis), exercise therapy, physical therapy, and SNRIs (e.g., duloxetine) generally have better or at least equal evidence and should usually be tried first [13] Strong evidence.
A reasonable framing: cannabis is a legitimate option to consider when first-line treatments have failed or caused intolerable side effects, particularly for neuropathic pain. It is not a replacement for evidence-based standard care as a first move.
Risks and Side Effects
Common, usually mild: dizziness, dry mouth, sedation, cognitive slowing, anxiety, increased appetite [2][3] Strong evidence. These cause many people to stop in trials.
More serious:
- Psychiatric. THC can precipitate or worsen psychosis in vulnerable individuals; risk rises with high-THC products and frequent use [14] Strong evidence.
- Cannabis use disorder. Roughly 9–10% of adult users develop dependence; higher with daily use [15] Strong evidence.
- Cardiovascular. Acute THC use raises heart rate and may increase risk of cardiovascular events in older patients or those with existing disease [16] Weak / limited.
- Driving impairment. Real and dose-dependent Strong evidence.
- Cannabinoid hyperemesis syndrome. Paradoxical severe vomiting in some chronic heavy users Strong evidence.
- Drug interactions. CBD inhibits several cytochrome P450 enzymes and can raise levels of many drugs, including some anticonvulsants and blood thinners [17] Strong evidence.
Smoked cannabis also carries respiratory irritation risks; vaporization and oral products avoid combustion byproducts.
Sources
- Government National Academies of Sciences, Engineering, and Medicine. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. Washington, DC: The National Academies Press; 2017. ↗
- Peer-reviewed Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. JAMA. 2015;313(24):2456-2473.
- Peer-reviewed Fisher E, Moore RA, Fogarty AE, et al. Cannabinoids, cannabis, and cannabis-based medicines for pain management: a systematic review of randomised controlled trials. Pain. 2021;162(Suppl 1):S45-S66.
- Peer-reviewed Mücke M, Phillips T, Radbruch L, Petzke F, Häuser W. Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database of Systematic Reviews. 2018;3:CD012182.
- Government European Medicines Agency / national approvals summary for nabiximols (Sativex), indicated for MS spasticity. GW Pharma / Bayer prescribing information. ↗
- Peer-reviewed Walitt B, Klose P, Fitzcharles MA, Phillips T, Häuser W. Cannabinoids for fibromyalgia. Cochrane Database of Systematic Reviews. 2016;7:CD011694.
- Peer-reviewed Baron EP. Medicinal Properties of Cannabinoids, Terpenes, and Flavonoids in Cannabis, and Benefits in Migraine, Headache, and Pain: An Update on Current Evidence and Cannabis Science. Headache. 2018;58(7):1139-1186.
- Peer-reviewed Boehnke KF, Litinas E, Clauw DJ. Medical Cannabis Use Is Associated With Decreased Opiate Medication Use in a Retrospective Cross-Sectional Survey of Patients With Chronic Pain. Journal of Pain. 2016;17(6):739-744.
- Peer-reviewed Shover CL, Davis CS, Gordon SC, Humphreys K. Association between medical cannabis laws and opioid overdose mortality has reversed over time. PNAS. 2019;116(26):12624-12626.
- Peer-reviewed Gulbransen G, Xu W, Arroll B. Cannabidiol prescription in clinical practice: an audit on the first 400 patients in New Zealand. BJGP Open. 2020;4(1).
- Peer-reviewed Piomelli D, Russo EB. The Cannabis sativa Versus Cannabis indica Debate: An Interview with Ethan Russo, MD. Cannabis and Cannabinoid Research. 2016;1(1):44-46.
- Government Centers for Disease Control and Prevention. Drug Overdose Death Rates. National Center for Health Statistics, ongoing. ↗
- Government Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022. MMWR Recomm Rep. 2022;71(3):1-95.
- Peer-reviewed Di Forti M, Quattrone D, Freeman TP, et al. The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. Lancet Psychiatry. 2019;6(5):427-436.
- Peer-reviewed Hasin DS, Saha TD, Kerridge BT, et al. Prevalence of Marijuana Use Disorders in the United States Between 2001-2002 and 2012-2013. JAMA Psychiatry. 2015;72(12):1235-1242.
- Peer-reviewed Page RL, Allen LA, Kloner RA, et al. Medical Marijuana, Recreational Cannabis, and Cardiovascular Health: A Scientific Statement From the American Heart Association. Circulation. 2020;142(10):e131-e152.
- Peer-reviewed Brown JD, Winterstein AG. Potential Adverse Drug Events and Drug-Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use. Journal of Clinical Medicine. 2019;8(7):989.
How this page was made
Generation history
Drafting assistance and fact-check automation are used, with a human operator spot-checking on a weekly basis. See how articles are made.
Related
- Cannabis Use Disorder — A real DSM-5 diagnosis affecting roughly 1 in 5 regular users, with modest but growing evi...